The association between BMI and BSA–temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525

BACKGROUND: Fearing increased myelotoxicity, many practitioners adjust the body surface area (BSA)-calculated doses in obese patients. Regarding temozolomide (TMZ), a prior study suggested men with a BSA >2 m(2) may experience increased toxicity; however, surprisingly, the inverse observation was...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurooncol Pract
Autors principals: Robins, H Ian, Eickhoff, Jens, Gilbert, Mark R, Armstrong, Terri S, Shi, Wenyin, De Groot, John F, Schultz, Christopher J, Hunter, Grant K, Valeinis, Egils, Roach, Mack, Youssef, Emad F, Souhami, Luis, Howard, Steve P, Lieberman, Frank S, Herman, James G, Zhang, Peixin, Mehta, Minesh P
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6899045/
https://ncbi.nlm.nih.gov/pubmed/31832217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/nop/npz006
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars